The grant has been awarded by the Australian Government's National Health and Medical Research Council (NHMRC), and will be matched by the South Australian...
Dedicaid's core asset is a clinical decision support software (CDSS) AI platform capable of rapidly generating indication-specific CDSS applications from a...
Expanded facility to manufacture mRNA-based therapies and vaccines Researchers at the University of Adelaide will address the design and manufacturi...
In April 2022, Telix secured the exclusive worldwide rights to develop and commercialise radiolabelled forms of olaratumab for the diagnosis and treatment ...
The increased presence in the U.S. comes as Atmo Biosciences prepares to begin a multi-site pivotal study to support a U.S. Food and Drug Administration (F...
The newly acquired facility and team is in Bentley, a suburb of Perth in Western Australia. It will operate as a Contract Development and Manufacturing Org...
Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer tre...
Sandoz plans to acquire worldwide product rights for Mycamine® (micafungin sodium) from Astellas Acquiring leading global echinocandin, one of three...
Receives greenlight from the FDA for Phase 1/2a clinical trial of CNA3103 On track to commence patient enrollment during the first half 2023 Carina B...
© 2024 Biopharma Boardroom. All Rights Reserved.
